Moshe Giladi

ORCID

Publication Activity (10 Years)

Years Active: 2017-2023
Publications (10 Years): 9

Top Venues

International journal of molecular sciences

Cancers

Radiation oncology (London, England)

Biomolecules

This page only lists publications with an associated author ORCID identifier.

Publications

Dietmar Krex, Paula Bartmann, Doris Lachmann, Alexander Hagstotz, Willi Jugel, Rosa S Schneiderman, Karnit Gotlib, Yaara Porat, Katja Robel, Achim Temme, Moshe Giladi, Susanne Michen
Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas. International journal of molecular sciences 24 (5) (2023)
Dietmar Krex, Paula Bartmann, Doris Lachmann, Alexander Hagstotz, Willi Jugel, Rosa S Schneiderman, Karnit Gotlib, Yaara Porat, Katja Robel, Achim Temme, Moshe Giladi, Susanne Michen
Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas. International journal of molecular sciences 24 (5) (2023)
Dietmar Krex, Paula Bartmann, Doris Lachmann, Alexander Hagstotz, Willi Jugel, Rosa S Schneiderman, Karnit Gotlib, Yaara Porat, Katja Robel, Achim Temme, Moshe Giladi, Susanne Michen
Aurora B Kinase Inhibition by AZD1152 Concomitant with Tumor Treating Fields Is Effective in the Treatment of Cultures from Primary and Recurrent Glioblastomas. International journal of molecular sciences 24 (5) (2023)
Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, Antonia Martinez-Conde, Ori Braten, Catherine Tempel-Brami, Einav Zeevi, Roni Frechtel-Gerzi, Hila Ene, Eyal Dor-On, Tali Voloshin, Itai Tzchori, Adi Haber, Moshe Giladi, Adrian Kinzel, Uri Weinberg, Yoram Palti
Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo . Cancers 2022, 14 , 2959. Cancers 15 (4) (2023)
Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, Antonia Martinez-Conde, Ori Braten, Catherine Tempel-Brami, Einav Zeevi, Roni Frechtel-Gerzi, Hila Ene, Eyal Dor-On, Tali Voloshin, Itai Tzchori, Adi Haber, Moshe Giladi, Adrian Kinzel, Uri Weinberg, Yoram Palti
Correction: Davidi et al. Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo . Cancers 2022, 14 , 2959. Cancers 15 (4) (2023)
Shiri Davidi, Sara Jacobovitch, Anna Shteingauz, Antonia Martinez-Conde, Ori Braten, Catherine Tempel-Brami, Einav Zeevi, Roni Frechtel-Gerzi, Hila Ene, Eyal Dor-On, Tali Voloshin, Itai Tzchori, Adi Haber, Moshe Giladi, Adrian Kinzel, Uri Weinberg, Yoram Palti
Tumor Treating Fields (TTFields) Concomitant with Sorafenib Inhibit Hepatocellular Carcinoma In Vitro and In Vivo . Cancers 14 (12) (2022)
Yiftah Barsheshet, Tali Voloshin, Boris Brant, Gadi Cohen, Lilach Koren, Roni Blatt, Shay Cahal, Tharwat Haj Khalil, Efrat Zemer Tov, Rom Paz, Anat Klein-Goldberg, Catherine Tempel-Brami, Sara Jacobovitch, Alexandra Volodin, Tal Kan, Bella Koltun, Cfir David, Adi Haber, Moshe Giladi, Uri Weinberg, Yoram Palti
Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model. International journal of molecular sciences 23 (22) (2022)
Ellaine Salvador, Almuth F Kessler, Dominik Domröse, Julia Hörmann, Clara Schaeffer, Aiste Giniunaite, Malgorzata Burek, Catherine Tempel-Brami, Tali Voloshin, Alexandra Volodin, Adel Zeidan, Moshe Giladi, Ralf-Ingo Ernestus, Mario Löhr, Carola Yvette Förster, Carsten Hagemann
Tumor Treating Fields (TTFields) Reversibly Permeabilize the Blood-Brain Barrier In Vitro and In Vivo. Biomolecules 12 (10) (2022)
Moshe Giladi, Mijal Munster, Rosa S Schneiderman, Tali Voloshin, Yaara Porat, Roni Blat, Katarzyna Zielinska-Chomej, Petra Hååg, Ze'ev Bomzon, Eilon D Kirson, Uri Weinberg, Kristina Viktorsson, Rolf Lewensohn, Yoram Palti
Tumor treating fields (TTFields) delay DNA damage repair following radiation treatment of glioma cells. Radiation oncology (London, England) 12 (1) (2017)

Moshe Giladi.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Moshe Giladi